Compare Stocks

Aben Minerals Ltd. engages in the acquisition and exploration of mineral properties primarily in British Columbia, Saskatchewan, and Yukon, Canada. The company primarily explores for gold and graphite deposits. Its flagship project is the Forrest Kerr Gold project that covers an area of 23,397 hectares located in northwestern British Columbia. The company was formerly known as Aben Resources Ltd. and changed its name to Aben Minerals Ltd. in February 2023. Aben Minerals Ltd. was incorporated in 1960 and is headquartered in Vancouver, Canada.

Alacer Gold Corp. engages in the mining, development, and exploration of mineral deposits in Turkey. It primarily holds an 80% interest in the Ãöpler gold mine that is located in the Erzincan Province, east-central Turkey. The company was incorporated in 1993 and is based in Denver, Colorado.

Anaconda Mining Inc. operates as a gold mining, development, and exploration company in Canada. It holds a 100% interest in the Point Rousse project comprising 6 mining leases and 7 mineral licenses with a total of 5,552 hectares located in the Baie Verte Mining District, Newfoundland; and the Goldboro Gold project comprising 37 contiguous claims covering an area of 592 hectares situated to the northeast of Halifax, Nova Scotia. The company also holds a 100% interest in the Tilt Cove property that covers an area of approximately 11,000 hectares located within the Baie Verte Mining District. Anaconda Mining Inc. was incorporated in 1994 is headquartered in Toronto, Canada.

Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.

Multi-Metal Development Ltd., a mineral exploration and development company, focuses on identifying, acquiring, and developing natural resource opportunities in the United States, Austria, and Canada. The company explores for molybdenum, copper, silver, tungsten, zinc, germanium, lead, fluorite, cadmium, and rhenium deposits. Its flagship project comprises the CuMo molybdenum project that consists of 105 unpatented mineral claims located in south-central Idaho, the United States. The company was formerly known as American CuMo Mining Corporation. Multi-Metal Development Ltd. was incorporated in 1971 and is headquartered in Vancouver, Canada.